Overview

Budesonide Capsules Versus Mesalazine Granules in Active Ulcerative Colitis (UC)

Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to prove the therapeutic equivalence and safety of once-daily 9 mg budesonide versus 3 g mesalazine in a 8-week treatment in patients with active ulcerative colitis.
Phase:
Phase 3
Details
Lead Sponsor:
Dr. Falk Pharma GmbH
Treatments:
Budesonide
Mesalamine